Ruggero Ridolfi

3.5k total citations
97 papers, 2.4k citations indexed

About

Ruggero Ridolfi is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ruggero Ridolfi has authored 97 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 48 papers in Immunology and 30 papers in Molecular Biology. Recurrent topics in Ruggero Ridolfi's work include Immunotherapy and Immune Responses (46 papers), Cancer Immunotherapy and Biomarkers (35 papers) and CAR-T cell therapy research (26 papers). Ruggero Ridolfi is often cited by papers focused on Immunotherapy and Immune Responses (46 papers), Cancer Immunotherapy and Biomarkers (35 papers) and CAR-T cell therapy research (26 papers). Ruggero Ridolfi collaborates with scholars based in Italy, United States and India. Ruggero Ridolfi's co-authors include Laura Ridolfi, Vanna Chiarion‐Sileni, Angela Riccobon, David M. Berman, David R. Minor, Omid Hamid, Jeffrey S. Weber, Hazem Assi, Paola Queirolo and Asim Amin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Ruggero Ridolfi

91 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruggero Ridolfi Italy	25	1.9k	1.1k	774	408	175	97	2.4k
Parisa Momtaz United States	14	1.5k 0.8×	499 0.4×	353 0.5×	362 0.9×	77 0.4×	40	1.8k
Leila Khoja United Kingdom	20	1.7k 0.9×	403 0.4×	416 0.5×	612 1.5×	88 0.5×	50	2.1k
Ramy Ibrahim United States	24	2.0k 1.1×	1.2k 1.0×	430 0.6×	462 1.1×	16 0.1×	66	2.4k
Hussein Tawbi United States	24	1.1k 0.6×	382 0.3×	739 1.0×	694 1.7×	25 0.1×	108	2.0k
Ryan D. Gentzler United States	20	2.1k 1.1×	426 0.4×	285 0.4×	1.4k 3.4×	29 0.2×	86	2.5k
Oliver Bohnsack United States	5	2.0k 1.1×	957 0.8×	386 0.5×	700 1.7×	13 0.1×	12	2.4k
J. J. Bonerandi France	14	783 0.4×	171 0.2×	464 0.6×	342 0.8×	46 0.3×	25	1.4k
Osama E. Rahma United States	28	2.1k 1.1×	1.0k 0.9×	485 0.6×	520 1.3×	17 0.1×	113	2.9k
Gisele W. B. Colleoni Brazil	21	590 0.3×	428 0.4×	678 0.9×	185 0.5×	17 0.1×	85	1.5k
Andrea Warrick United States	17	607 0.3×	185 0.2×	499 0.6×	285 0.7×	63 0.4×	25	1.2k

Countries citing papers authored by Ruggero Ridolfi

Since Specialization

Citations

This map shows the geographic impact of Ruggero Ridolfi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruggero Ridolfi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruggero Ridolfi more than expected).

Fields of papers citing papers by Ruggero Ridolfi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruggero Ridolfi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruggero Ridolfi. The network helps show where Ruggero Ridolfi may publish in the future.

Co-authorship network of co-authors of Ruggero Ridolfi

This figure shows the co-authorship network connecting the top 25 collaborators of Ruggero Ridolfi. A scholar is included among the top collaborators of Ruggero Ridolfi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruggero Ridolfi. Ruggero Ridolfi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascierto, Paolo A., Keith T. Flaherty, Paola Queirolo, et al.. (2014). Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. Journal of Clinical Oncology. 32(15_suppl). TPS9105–TPS9105. 3 indexed citations

Altomonte, Maresa, Anna Maria Di Giacomo, Paola Queirolo, et al.. (2013). Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. Journal of Experimental & Clinical Cancer Research. 32(1). 82–82. 20 indexed citations

Ridolfi, Laura, Massimiliano Petrini, Anna Maria Granato, et al.. (2013). Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. Journal of Translational Medicine. 11(1). 135–135. 58 indexed citations

Maio, Michele, Paolo A. Ascierto, Alessandro Testori, et al.. (2012). The cost of unresectable stage III or stage IV melanoma in Italy. Journal of Experimental & Clinical Cancer Research. 31(1). 91–91. 26 indexed citations

Giacomo, Anna Maria Di, Paolo A. Ascierto, Lorenzo Pilla, et al.. (2012). Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.. Journal of Clinical Oncology. 30(15_suppl). 8513–8513. 5 indexed citations

Maio, Michele, Alessandro Testori, Paolo A. Ascierto, et al.. (2012). The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.. Journal of Clinical Oncology. 30(15_suppl). 8529–8529. 5 indexed citations

Ascierto, Paolo A., Paola Queirolo, Lorenzo Pilla, et al.. (2011). 9305 ORAL A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma – the NIBIT-M1 Trial. European Journal of Cancer. 47. S653–S654. 1 indexed citations

Chiarion‐Sileni, Vanna, Michele Guida, Antonella Romanini, et al.. (2011). Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874].. Journal of Clinical Oncology. 29(15_suppl). 8506–8506. 15 indexed citations

Farolfi, Alberto, Laura Ridolfi, Massimo Guidoboni, et al.. (2011). Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study. Journal of Chemotherapy. 23(5). 300–305. 14 indexed citations

10.

Weber, Jeffrey S., John A. Thompson, Omid Hamid, et al.. (2009). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. Clinical Cancer Research. 15(17). 5591–5598. 460 indexed citations

11.

Ridolfi, Laura, Massimiliano Petrini, Laura Fiammenghi, Angela Riccobon, & Ruggero Ridolfi. (2008). Human embryo immune escape mechanisms rediscovered by the tumor. Immunobiology. 214(1). 61–76. 18 indexed citations

12.

Ridolfi, Laura, Delia Cangini, Riccardo Galassi, et al.. (2008). Reversible, PET-positive, Generalized Lymphadenopathy and Splenomegaly During High-dose Interferon-α-2b Adjuvant Therapy for Melanoma. Journal of Immunotherapy. 31(7). 675–678. 5 indexed citations

13.

Guida, Michele, Angela Riccobon, Guido Biasco, et al.. (2006). Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Research. 16(4). 317–323. 7 indexed citations

14.

Ridolfi, Ruggero, Antonella Romanini, Vanna Chiarion‐Sileni, et al.. (2004). Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Research. 14(4). 295–299. 18 indexed citations

15.

Ridolfi, Laura, Ruggero Ridolfi, Angela Riccobon, et al.. (2003). Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma. Journal of Immunotherapy. 26(2). 156–162. 17 indexed citations

16.

Ridolfi, Ruggero, Laura Ridolfi, Massimiliano Petrini, Laura Fiammenghi, & Angela Riccobon. (2003). Dendritic cell vaccination and immunostimulation in advanced melanoma. Expert Review of Vaccines. 2(6). 825–833. 4 indexed citations

17.

Castagneto, B., Silvia Zai, Luciano Mutti, et al.. (2001). Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion. Lung Cancer. 31(2-3). 303–310. 67 indexed citations

18.

Bruzzone, Milena, A. Rubagotti, Angiolo Gadducci, et al.. (1997). Intraperitoneal Carboplatin with or without Interferon-α in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients. Gynecologic Oncology. 65(3). 499–505. 24 indexed citations

19.

Ridolfi, Ruggero, Roberta Maltoni, Angela Riccobon, et al.. (1994). A Phase II Study of Advanced Colorectal Cancer Patients Treated with Combination 5-Fluorouracil Plus Leucovorin and Subcutaneous Interleukin-2 Plus Alpha Interferon. Journal of Chemotherapy. 6(4). 265–271. 5 indexed citations

20.

Ridolfi, Ruggero, et al.. (1991). Chemotherapy with 5-Fluorouracil and Streptozotocin in Carcinoid Tumors of Gastrointestinal Origin: Experiences with 13 Patients. Journal of Chemotherapy. 3(5). 328–331. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact